Pharmaceutical company AbbVie will unveil its first-quarter earnings Thursday, giving investors and industry observers their first glimpse of what a full quarter of sales looks like for its new hepatitis C treatment.
Novartis subsidiary Sandoz received approval from the Food and Drug Administration Thursday to market the drug Glatopa, the first generic alternative for Teva Pharmaceutical's multiple sclerosis treatment Copaxone.
John Castellani, Pharmaceutical Research and Manufacturers of America president and CEO, plans to retire from the post at the beginning of next year.
Spending in the U.S. on prescription drugs rose by 13% in 2014, driven largely by increased spending on new breakthrough medications, according to a new report. And Medicaid patients' spending on drugs rose much faster in states that expanded Medicaid under the ACA compared with those that did not.
An advisory panel to the U.S. Food and Drug Administration voted Tuesday to recommend the agency require drugmaker AstraZeneca to change the labeling of its diabetes medication Onglyza to add safety information to reflect a heightened risk for heart failure associated with its use.
The Centers for Disease Control and Prevention said Tuesday that it has launched a clinical trial in Sierra Leone of the experimental Ebola vaccine that showed positive results in two previous trials.
Approval by the Food and Drug Administration of the new PCSK9 inhibitors would be an enormous boon to the drugmakers that developed them.
If left untreated, Stacey Lane's level of bad cholesterol would soar to more than four times what heart experts recommend. Help for her genetic disorder could come in the form of a new category of injectable drugs known as PCSK9 inhibitors, but it won't be cheap.
A preliminary report by the U.S. Food and Drug Administration said AstraZeneca's diabetes drug Onglyza was associated with a higher risk of death and heart failure, raising new concerns over a class of diabetes medications that has been linked to heart failure complications.
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
Last month, the Food and Drug Administration approved the first biosimilar in the U.S.—Sandoz's Zarxio, a biosimilar version of Amgen's Neupogen (filgrastim). This effectively launches a new industry—one where lower-cost biosimilars will eventually create a competitive market.
Major pharmaceutical companies continue to actively oppose a yet-to-be-finalized proposed rule that would require generic drug companies to update labels on products if they receive new safety information.